Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Biora Therapeutics, Inc. - Common Stock (NQ: BIOR )

2.790 +0.250 (+9.84%)
Streaming Delayed Price Updated: 12:19 PM EST, Nov 11, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Biora Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 Next >
Biora Therapeutics to Report Second Quarter 2023 Financial Results and Provide Corporate Update
From Biora Therapeutics, Inc.
Via GlobeNewswire
Biora Therapeutics Continues to Monetize Legacy Diagnostics Assets
From Biora Therapeutics, Inc.
Via GlobeNewswire
Biora Therapeutics Announces New Patents for its NaviCap™ Targeted Oral Delivery Platform
From Biora Therapeutics, Inc.
Via GlobeNewswire
Recap: Biora Therapeutics Q1 Earnings
Via Benzinga
Earnings Preview: Biora Therapeutics
Via Benzinga
Biora Therapeutics Earnings Perspective: Return On Invested Capital
Via Benzinga
Earnings Preview For Biora Therapeutics
Via Benzinga
Biora Therapeutics Presents Data on the BioJet™ Systemic Oral Delivery Platform at the American Diabetes Association 83rd Scientific Sessions
An average bioavailability of 37% for a GLP-1 receptor agonist was achieved in animals 
From Biora Therapeutics, Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Tuesday's Intraday Session
Via Benzinga
Dow Surges 100 Points; US Inflation Rate Drops In May
U.S. stocks traded higher this morning, with Dow Jones gaining over 100 points on Tuesday. Following the market opening Tuesday, the Dow traded up 0.32% to 34,173.85 while the NASDAQ rose 0.72% to... 
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Via Benzinga
Why Motorcar Parts of America Shares Are Trading Higher By 13%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Gainers First Wave BioPharma, Inc. (NASDAQ: FWBI) shares gained 143% to $2.77 after the company achieved its enrollment target for its adrulipase Phase 2 SPAN trial for exocrine pancreatic... 
Via Benzinga
Biora Therapeutics Announces $8 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
From Biora Therapeutics, Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Friday's Intraday Session
Via Benzinga
Biora Therapeutics to Present Preclinical Data on the BioJet™ Systemic Oral Delivery Platform at the 59th Annual Meeting of the European Association for the Study of Diabetes
From Biora Therapeutics, Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Wednesday's Intraday Session
Via Benzinga
3 Biotech Stocks That Could Turn $1,000 into $10,000 by 2024
These biotech stocks with high return potential are poised to provide quick returns for investors who invest over the next year. 
Via InvestorPlace
Biora Therapeutics Provides Corporate Update and Reports First Quarter 2023 Financial Results
From Biora Therapeutics, Inc.
Via GlobeNewswire
Biora Therapeutics to Report First Quarter 2023 Financial Results and Provide Corporate Update
From Biora Therapeutics, Inc.
Via GlobeNewswire
Biora Therapeutics Appoints Dr. Ariella Kelman as Chief Medical Officer
From Biora Therapeutics, Inc.
Via GlobeNewswire
Biora Therapeutics to Participate in Crohn’s & Colitis Foundation’s IBD Innovate Conference
From Biora Therapeutics, Inc.
Via GlobeNewswire
Biora Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full-Year 2022 Financial Results
From Biora Therapeutics, Inc.
Via GlobeNewswire
Biora Therapeutics to Report Fourth Quarter and Full Year 2022 Financial Results and Provide Corporate Update
From Biora Therapeutics, Inc.
Via GlobeNewswire
What Does Biora Therapeutics' Debt Look Like?
Over the past three months, shares of Biora Therapeutics Inc. (NASDAQ:BIOR) moved lower by 46.87%. When understanding a companies price change over a time period like 3 months, it could be helpful to... 
Via Benzinga
Biora Therapeutics Announces Bioavailability Results for Oral Delivery of GLP-1 Receptor Agonist
Preclinical data demonstrate potential to orally deliver peptides and monoclonal antibodies at bioavailability levels more than double the company’s current target 
From Biora Therapeutics, Inc.
Via GlobeNewswire
Biora Therapeutics Announces Improved Bioavailability Results for its Systemic Delivery Platform
Average bioavailability greater than 50% with high consistency observed in animal study 
From Biora Therapeutics, Inc.
Via GlobeNewswire
10 Short Squeeze Candidates To Watch This Week: Getty Images, PaxMedica And This Meme Stock Retailer
Potential short squeeze plays gained steam in 2021 and continued through 2022, with new traders looking for the next huge move. High short interest and a high cost to borrow are among the common traits... 
Via Benzinga
Biora Therapeutics' Debt Overview
Over the past three months, shares of Biora Therapeutics Inc. (NASDAQ:BIOR) decreased by 61.54%. When understanding a companies price change over a time period like 3 months, it could be helpful to... 
Via Benzinga
Biora Therapeutics Presents Data from Device Performance Study with Repeat Doses in Both Fasted and Fed States at Crohn’s & Colitis Congress
Study demonstrates targeted delivery devices functioned as designed when administered with food, potentially enabling non-fasted administration 
From Biora Therapeutics, Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Monday's Intraday Session
Via Benzinga
< Previous 1 2 3 4 5 6 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.